Results 201 to 210 of about 28,829 (241)

Caspofungin: a review of its characteristics, activity, and use in intensive care units

Expert Review of Anti-Infective Therapy, 2020
Introduction Candidemia is the fourth frequent reason of healthcare-related bloodstream infections in critically ill patients. For initial management of (suspected) invasive candidiasis in critically ill patients, usage of an echinocandin, e.g ...
S. Hashemian, T. Farhadi, A. Velayati
semanticscholar   +1 more source

Caspofungin

Reactions Weekly
Stephanie J. Phelps, Tracy M. Hagemann, Kelley R. Lee   +2 more
  +8 more sources

Impact of calmodulin inhibition by fluphenazine on susceptibility, biofilm formation and pathogenicity of caspofungin-resistant Candida glabrata.

Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND In recent decades, Candida glabrata has emerged as a frequent cause of life-threatening fungal infection. In C. glabrata, echinocandin resistance is associated with mutations in FKS1/FKS2 (β-1,3-glucan synthase).
A. Ceballos Garzón, Daniela Amado, Estelle Robert, C. M. Parra Giraldo, P. Le Pape   +4 more
semanticscholar   +1 more source

Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris.

Journal of Antimicrobial Chemotherapy, 2019
BACKGROUND Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C.
Catiana Dudiuk, I. Berrio, Florencia Leonardelli, Soraya E Morales-López, Laura Theill, Daiana Macedo, José Yesid-Rodriguez, S. Salcedo, Adriana Marín, S. Gamarra, G. García-Effrón   +10 more
semanticscholar   +1 more source

Super absorbent chitosan-based hydrogel sponges as carriers for caspofungin antifungal drug.

International journal of pharmaceutics, 2021
M. Lazaridou, S. Nanaki, Alexandra Zamboulis, Chrysanthi Papoulia, K. Chrissafis, P. Klonos, A. Kyritsis, Souzan Vergkizi-Nikolakaki, M. Kostoglou, D. Bikiaris   +9 more
semanticscholar   +1 more source

High initial (1, 3) Beta-D-Glucan concentration may be a predictor of satisfactory caspofungin combined with TMP/SMZ response to HIV-negative patients with moderate to severe pneumocystis jirovecii pneumonia.

International Journal of Infectious Diseases, 2019
OBJECTIVES The aim of this study was to investigate the efficacy of combination therapy of caspofungin and TMP/SMZ (trimethoprim/sulfamethoxazole) in moderate to severe pneumocystis jirovecii pneumonia (PJP) in patients without human immunodeficiency ...
F. Jin, Xiao-hang Liu, Wenhui Chen, Zhang Fan, Huan-ling Wang   +4 more
semanticscholar   +1 more source

Genotypic and phenotypic characterization of Candida albicans Lebanese hospital isolates resistant and sensitive to caspofungin.

Fungal Genetics and Biology, 2019
The fungus Candida albicans is both a commensal and an opportunistic human pathogen, present as part of the normal human microflora causing serious mucosal, and systemic life threatening infections.
M. Toutounji, S. Tokajian, R. Khalaf
semanticscholar   +1 more source

Caspofungin

Reactions Weekly, 2023
openaire   +2 more sources

Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study

Clinical Pharmacokinetics, 2021
Nicolas Garbez, L. Mbatchi, S. Wallis, L. Muller, J. Lipman, J. Roberts, J. Lefrant, C. Roger   +7 more
semanticscholar   +1 more source

Caspofungin: an overview

Expert Review of Anti-infective Therapy, 2005
The echinocandins are a novel class of antifungal agents that have come into use over the past 10 years. The mechanism of action of these lipopeptide agents is via noncompetitive inhibition of the synthesis of 1,3-beta-glucans, which are fungal cell wall constituents. All agents of this class are only available in an intravenous formulation.
openaire   +2 more sources